Germany to India: Syringe Import Trade Route
India has recorded 820 verified shipments of Syringe imported from Germany, representing a combined trade value of $138.4B USD. This corridor is served by 72 active Germany exporters, with an average shipment value of $168.8M USD. The leading Germany supplier is GLAXOSMITHKLINE BIOLOGICALS SA , which accounts for 100% of total import value with 4 shipments worth $138.0B USD. On the buying side, GLAXOSMITHKLINE PHARMACEUTICALS LIMITED is the largest Indian importer with $138.0B USD in purchases. The top 3 suppliers — GLAXOSMITHKLINE BIOLOGICALS SA , F. HOFFMANN -LA ROCHE LTD , NOVARTIS PHARMA AG — together control 100% of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill of entry records. Values reported in FOB USD.
Route Intelligence Overview
The Germany to India Syringe corridor is one of India's established pharmaceutical import routes from Germany, with 820 shipments documented worth a combined $138.4B USD. The route is dominated by GLAXOSMITHKLINE BIOLOGICALS SA , which alone accounts for roughly 100% of all import value, reflecting the consolidated nature of Germany's syringe export sector.
Across 72 active Germany suppliers, the average shipment value stands at $168.8M USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (67%) and air (17%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.
Shipment activity peaks during January–March, with an average transit time of 30 days port-to-port. The route has recorded an annual growth rate of 11.7%, placing it at rank #15 among India's top syringe import origins globally.
On the Indian buyer side, key Indian importers include GLAXOSMITHKLINE PHARMACEUTICALS LIMITED , ROCHE PRODUCTS (INDIA) PRIVATE LIMITED , NOVARTIS HEALTHCARE PRIVATE LIMITED and 50 others. GLAXOSMITHKLINE PHARMACEUTICALS LIMITED is the single largest Indian importer with 4 shipments valued at $138.0B USD.
